Zinzani 2012

Methods	Secondary citation(s) Zinzani 2006 Language of publication English Study design Retrospective, multi‐centre study (2 centres) Study centre(s) Bologna and Florence, Italy Country Italy Median follow‐up time (range) 45 months (6‐100)
Participants	Number of included participants 304 Inclusion criteria Diagnosed with HL Exclusion criteria Other treatment regimens than ABVD Secondary lymphomas Continuation of therapy during data analysis Consent Yes; written informed consent Recruitment period June 1997 to June 2009 Age (range, in years) 32 (13‐78) Ethnic group(s) Not reported Stages of disease All stages Comorbidities Assessed, but not reported Therapy regimen ABVD dependent on disease stage: early stages 6x ABVD or 4x ABVD with radiotherapy; advanced stages 6x ABVD
Prognostic factor(s)	Prognostic factor(s) Interim PET Definition of prognostic factor(s) Not reported Timing of prognostic factor measurement After cycle 2 of ABVD Method for measurement (use of specific scale and cut‐off) Juweid criteria PET positive considered if focal FDG uptake that could not be attributed to physiological biodistribution, benign uptake or normal anatomy, with clearly increased activity relative to the background, excluding participants with minimal residual uptake 2 experienced board‐certified nuclear medicine physicians interpreted all scans Was the same definition and method for measurement used in all participants? Yes Were prognostic factor(s) assessed blinded for outcome(s), and for each other (if relevant)? No
Notes	Conflict of interest None Funding This work was partially supported by BolognAIL (Bologna, Italy).

ABVD: adriamycin/doxorubicin, bleomycin, vinblastine and dacarbazine; BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone; ePET: early positron emission tomography; FDG: [18F]‐fluorodeoxy‐D‐glucose; HL: Hodgkin lymphoma; HR: hazard ratio; IF‐RT: involved‐field radiation therapy; ITT: intention‐to‐treat; IQR: interquartile range; NPV: negative predictive value; OS: overall survival; PET: positron emission tomography; PET‐CT: positron emission tomography computed tomography; PFS: progression‐free survival; PPV: positive predictive value.